The burgeoning landscape of therapy for obesity and type 2 glucose intolerance is currently witnessing considerable interest surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 target agonists, significant variations in their pharmacological profiles and clinical study results are emerging. Retatrutide, boast… Read More

Arriving in the landscape of excess body fat management, retatrutide presents a different strategy. Different from many current medications, retatrutide operates as a dual agonist, at once affecting both GLP peptide-1 (GLP-1) and glucose-responsive insulinotropic hormone (GIP) binding sites. This simultaneous engagement encourages several helpful e… Read More